[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053763":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":66,"collaborators":42,"id":69,"slug":42,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":42,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":42,"enrollmentInfo":77,"targetDuration":42,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":42,"overallStatus":86,"whyStopped":42,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Miami","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cetirizine Group","EXPERIMENTAL","Participants in this group will receive a single oral dose of cetirizine as a pre-medication administered 30-60 minutes before their scheduled standard-of-care anti-CD20 infusion therapy at each visit. Total participation duration is approximately 6 hours.",[13],"Drug: Cetirizine",{"label":15,"type":16,"description":17,"interventionNames":18},"Diphenhydramine Group","ACTIVE_COMPARATOR","Participants in this group will receive a single oral dose of diphenhydramine as a pre-medication administered 30-60 minutes before their scheduled standard-of-care anti-CD20 infusion therapy at each visit. Total participation duration is approximately 6 hours.",[19],"Drug: Diphenhydramine",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cetirizine","Participants will receive a single oral dose of cetirizine 10 mg administered 30-60 minutes before the scheduled standard-of-care anti-CD20 infusion at each visit.",[9],[27],"Zyrtec",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Diphenhydramine","Participants will receive a single oral dose of diphenhydramine 50 mg administered 30-60 minutes before the scheduled standard-of-care anti-CD20 infusion at each visit.",[15],[33],"Benadryl",[35],{"name":36,"affiliation":5,"role":37},"Jeffrey Hernandez, DNP, APRN","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","305-243-8873",null,"j.hernandez261@miami.edu",[45],{"facility":46,"status":42,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"UHealth Boca Raton","Boca Raton","Florida","33486","United States",{"type":52,"coordinates":53},"Point",[54,55],-80.0831,26.35869,{"lat":55,"lon":54},[58,60,61,64],{"name":59,"role":40,"phone":42,"phoneExt":42,"email":42},"Amy Barwell, RN",{"name":36,"role":37,"phone":42,"phoneExt":42,"email":42},{"name":62,"role":63,"phone":42,"phoneExt":42,"email":42},"Crystal Dixon, MD","SUB_INVESTIGATOR",{"name":65,"role":63,"phone":42,"phoneExt":42,"email":42},"Melissa Ortega, MD",{"type":37,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Jeffrey Hernandez","Supervisor, Advanced Practice Providers","100053763",false,"NCT07472413","Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project","Cetirizine Versus Diphenhydramine as a Pre-medication: Tolerability and Safety in Patients With MS Receiving Anti-Cluster of Differentiation 20 (CD20) Infusion Therapy","Inclusion Criteria:\n\n* Ages ≥18 years\n* Able to read and speak in English or Spanish\n* Able to and willing to give informed consent\n* Diagnosis of Multiple Sclerosis (MS)\n* Patients starting or currently receiving ocrelizumab, ublituximab, rituximab\n\nExclusion Criteria:\n\n* Adults unable or unwilling to consent\n* Patients younger than 18 years of age\n* Pregnant women\n* Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine\n* Moderate or severe renal impairment (creatinine clearance or 11-31 mL\u002Fmin or worse)\n* Patients with prior hypersensitivity reactions on additional preventative measures (e.g. H1 and H2\u002Fproton-pump inhibitor (PPI) the night prior to the infusion due to history of reactions)","ALL","18 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE3","The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.",[85],"Multiple Sclerosis","NOT_YET_RECRUITING","2026-07-09",{"date":89,"type":90},"2026-07-13","ACTUAL",{"date":92,"type":79},"2026-09-01",{"date":94,"type":79},"2028-07-01",{"name":5,"class":6},1]